|
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax®, a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For more information on Access Pharmaceuticals, Inc., click company logo for Web site and Yahoo! Finance quote above.
| Recent Price: |
$2.75 |
|
Fiscal Year End: |
December 31 |
| Float: |
2,750,000 |
|
Market Cap.: |
$47.5 million |
| Shares Out:* |
17,289,976 |
|
52-Week Price Range: |
$5.16–$1.00 |
|
|
|
* Assuming conversion of preferred stock |
June 26, 2008
June 17, 2008
June 5, 2008
June 5, 2008
June 4, 2008
May 28, 2008
May 28, 2008
May 14, 2008
May 5, 2008
April 24, 2008
April 17, 2008
April 15, 2008
March 19, 2008
March 6, 2008
January 8, 2008
December 26, 2007
November 14, 2007:
October 24, 2007:
September 11, 2007:
August 14, 2007:
June 26, 2007:
June 11, 2007:
June 5, 2007:
|
